Drug Trial Radar · NCT02726386
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
214
Actual
Start
May 4, 2016
Primary completion
Sep 9, 2019
Study completion Feb 2027
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
Conditions
- Parkinson's Disease
Interventions
ND0612Drug
ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (Long-term Safety)Time frame: Baseline to Month 12
- Percentages of Subjects Who Complete the 12-month Treatment Period or Discontinue Due to AE (Tolerability)Time frame: Baseline to Month 12
Locations
57 sites in 9 countries. Site status is shown where the registry gives one.
Xenoscience
Phoenix, Arizona
Clinical Trials Inc.
Little Rock, Arkansas
The Parkinsons and Movement Disorder Institute
Fountain Valley, California
Neuro Pain Medical Center
Fresno, California
University of Colorado Denver
Aurora, Colorado
Rocky Mountain Movement Disorders Center
Englewood, Colorado
Parkinson's Disease and Movement Disorder Center of Boca Raton
Boca Raton, Florida
MD Clinical
Hallandale, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
University of Florida Health at Jacksonville
Jacksonville, Florida
Neurology Associates, PA
Maitland, Florida
Parkinsons Disease Treatment Center of Southwest Florida
Port Charlotte, Florida
Suncoast Neuroscience Associates
St. Petersburg, Florida
Infinity Clinical Research, LLC
Sunrise, Florida
USF Health Parkinson's Disease and Movement Disorders
Tampa, Florida
Northwestern University
Chicago, Illinois
Unity Point Health
Des Moines, Iowa
University of Maryland, Neurology
Baltimore, Maryland
QUEST Research Institute
Farmington Hills, Michigan
Henry Ford Hospital
West Bloomfield, Michigan
Pyramid Clinical Research
Somerset, New Jersey
University of Cincinnati
Cincinnati, Ohio
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma
Synergy Trials
Richmond, Virginia
Sentara Neuroscience Institute
Virginia Beach, Virginia
Premier Research
Spokane, Washington
Medical University Innsbruck
Innsbruck, Austria
NEUROHK, s.r.o.
Choceň, Czechia
Clintrial s.r.o.
Prague, Czechia
Vestra Clinics, s.r.o.
Rychnov nad Kněžnou, Czechia
Centre Hospitalier d'Aix
Aix-en-Provence, France
CHU d'Amiens, Hopital Sud
Amiens, France
Hopital Neurologique Pierre Wertheimer
Bron, France
Hôpital Gabriel Montpied
Clermont-Ferrand, France
Hopital Roger Salengro
Lille, France
Hopital de la Timone
Marseille, France
CHU de Poitiers
Poitiers, France
Kliniken Beelitz GmbH
Beelitz-Heilstätten, Germany
St. Josefs Hospital
Bochum, Germany
Klinikum-Bremerhaven Reinkenheide
Bremerhaven, Germany
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.